AGENT FOR TREATING OR PREVENTING A DOMINANTLY-INHERITED DISEASE
An agent for treating a common form of autosomal dominant retinitis pigmentosa (ADRP) is disclosed, wherein the agent comprises a first nucleotide sequence encoding a CRISPR-associated (Cas) endonuclease which binds to an NG or NNGRRT PAM (protospacer adjacent motif) sequence, and a second nucleotide sequence encoding or comprising a guide RNA (gRNA) capable of forming a CRISPR-Cas complex with said Cas endonuclease, wherein the gRNA is specifically targeted to a target mutant allele selected from RHOP23H and NR2E3G56R.
1 .- 26 . (canceled)
27 . An agent for treating a common form of autosomal dominant retinitis pigmentosa (ADRP) in a subject, wherein said agent comprises:
(i) a first nucleotide sequence encoding a CRISPR-associated (Cas) endonuclease which binds to an NG protospacer adjacent motif (PAM) sequence; and
(ii) a second nucleotide sequence encoding or comprising a guide RNA (gRNA) capable of forming a CRISPR-Cas complex with said Cas endonuclease, wherein said gRNA is specifically targeted to:
a RHOP23H target mutant allele and comprises a targeting nucleotide sequence selected from the group consisting of SEQ ID NOs:3, 6 and 8; or
a NR2E3G56R target mutant allele and comprises a targeting nucleotide sequence selected from the group consisting of SEQ ID NOs:17 and 18.
28 . The agent of claim 27 , wherein the first nucleotide sequence encodes an SpCas9-NG endonuclease.
29 . The agent of claim 27 , wherein the target mutant allele is RHOP23H and the second nucleotide sequence encodes or comprises a gRNA comprising a targeting nucleotide sequence selected from the group consisting of SEQ ID NOs:3, 6 and 8.
30 . The agent of claim 29 , wherein the gRNA comprises the targeting nucleotide sequence of any one of SEQ ID NOs:3 and 6 operably linked to the scaffold nucleotide sequence of SEQ ID NO:29.
31 . The agent of claim 27 , wherein the target mutant allele is NR2E3G56R and the second nucleotide sequence encodes or comprises a gRNA comprising a targeting nucleotide sequence selected from the group consisting of SEQ ID NOs:17 and 18.
32 . The agent of claim 27 , wherein the first and second nucleotide sequences are provided on one or two viral vectors.
33 . The agent of claim 27 , wherein the first and second nucleotide sequences are provided in a delivery vector comprising nanoparticles composed of polymeric or other organic materials.
34 . A pharmaceutical composition comprising an agent according to claim 27 in combination with a pharmaceutically acceptable carrier, diluent and/or excipient.
35 . The pharmaceutical composition of claim 34 suitable for administration by sub-retinal injection.
36 . A method of treating a subject afflicted with, or predisposed to, autosomal dominant retinitis pigmentosa (ADRP), wherein the method comprises administering the pharmaceutical composition of claim 34 to the said subject.
37 . The method of claim 36 , wherein the method is commenced during adolescence.
38 . The method of claim 36 , wherein the method is commenced during childhood before ADRP disease onset and/or the appearance of ADRP symptoms.
39 . A CRISPR-Cas complex comprising a CRISPR-associated (Cas) endonuclease which binds to an NG PAM sequence and a gRNA, wherein said gRNA is specifically targeted to:
a RHOP23H target mutant allele and comprises a targeting nucleotide sequence selected from the group consisting of SEQ ID NOs:3, 6 and 8; or
a NR2E3G56R target mutant allele and comprises a targeting nucleotide sequence selected from the group consisting of SEQ ID NOs:17 and 18.
40 . The CRISPR-Cas endonuclease of claim 39 , wherein the Cas endonuclease is SpCas9-NG.
41 . The CRISPR-Cas complex of claim 40 , wherein the gRNA comprises the targeting nucleotide sequence of any one of SEQ ID NOs:3 and 6 operably linked to the scaffold nucleotide sequence of SEQ ID NO:29.